A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC

Clinical trial NCT07058519 · RECRUITING

Trial details

NCT number: NCT07058519
Sponsor: Shanghai Chest Hospital
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC)

Start date: 2025-09-23
Primary completion: 2029-01-24
Enrollment: 250

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.